Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR) Files An 8-K Regulation FD Disclosure

Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

Attached hereto as Exhibit 99.1 is a PowerPoint presentation that Citius Pharmaceuticals, Inc. will use for presentations to investors and healthcare conferences, and which is incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit No. Description
99.1 Corporate Presentation, Winter 2018.

Citius Pharmaceuticals, Inc. Exhibit
EX-99.1 2 f8k121118ex99-1_citius.htm CORPORATE PRESENTATION,…
To view the full exhibit click here

About Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR)

Citius Pharmaceuticals, Inc., formerly Trail One, Inc., is a pharmaceutical company engaged in developing and commercializing therapeutic products. The Company focuses on developing formulations to manage the delivery and compliance of approved drugs. The Company offers Suprenza, an orally disintegrating tablet and an obesity drug that can be administered with water or dissolved on tongue. The Company also focuses on development of its product candidate, Hydrocortisone-Lidocaine Cream, which is in Phase II study. Its Hydrocortisone-Lidocaine Cream is used to provide anti-inflammatory and anesthetic relief to persons suffering from grade I and II hemorrhoids. Citius Pharmaceuticals, LLC is its subsidiary. The Company has not generated any revenues.

An ad to help with our costs